{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:07:05Z","timestamp":1789387625787,"version":"build-2803163510"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, largely owing to profound therapeutic resistance driven by tumor heterogeneity, a highly immunosuppressive tumor microenvironment (TME), dense desmoplastic stroma, immune exclusion, and impaired antitumor immune surveillance. Although conventional chemotherapy provides limited clinical benefit, immune-based therapies have shown modest efficacy in unselected PDAC, highlighting the need for strategies that overcome the biological barriers underlying immune resistance. Recent advances in precision medicine and bioengineering have generated a diverse range of therapeutic platforms aimed at remodeling the PDAC ecosystem. This review evaluates oncolytic virotherapy, gene-editing technologies, engineered immune-cell therapies, nanotechnology-enabled delivery systems, and artificial intelligence (AI)-assisted precision oncology according to the PDAC barriers they are intended to address and the maturity of the supporting evidence. Oncolytic viruses may enhance tumor immunogenicity and reshape suppressive immune niches, whereas gene editing and engineered cellular therapies provide opportunities to target oncogenic vulnerabilities, improve immune-cell function, and overcome antigenic and stromal constraints. Nanotechnology-based platforms can modify tissue access, payload exposure, and local immune modulation in selected models, whereas AI approaches support molecular and spatial stratification and generate treatment-prioritization hypotheses. Most supporting evidence remains preclinical or early phase, and no platform class has established broad comparative clinical benefit in unselected PDAC. Translation remains constrained by intratumoral heterogeneity, delivery limitations, safety, manufacturing complexity, and insufficient predictive biomarkers. Translation will depend on biomarker-defined enrollment and on linking administered dose to tumor exposure, target engagement, biological activity, safety, and the added benefit of the investigational component. We therefore present a barrier-matched development framework rather than a validated treatment-assignment algorithm.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1900936","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:59:03Z","timestamp":1789387143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering strategies to address immune and delivery barriers in pancreatic ductal adenocarcinoma: a barrier-matched translational framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[{"name":"General Surgery Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]},{"name":"School of Nursing, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[{"name":"School of Nursing, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"School of Nursing, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qiang","family":"San","sequence":"additional","affiliation":[{"name":"School of Nursing, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-feng","family":"Ye","sequence":"additional","affiliation":[{"name":"General Surgery Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B2","volume-title":"NCCN clinical practice guidelines in oncology: Pancreatic adenocarcinoma","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B5","article-title":"Cancer stat facts: Pancreatic cancer","volume-title":"Surveillance, Epidemiology, and End Results Program","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","year":"2017","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: Integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","article-title":"Beyond just a tight fortress: Contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01157-1","article-title":"Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer","volume":"54","author":"Cui Zhou","year":"2022","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1038\/s41467-023-40895-6","article-title":"Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype","volume":"14","author":"Oh","year":"2023","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00197","article-title":"Real-world validation of the purity independent subtyping of tumors classifier for informing therapy selection in pancreatic ductal adenocarcinoma","volume":"9","author":"Wenric","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.03.002","article-title":"Fibroblasts in pancreatic cancer: Molecular and clinical perspectives","volume":"29","author":"Rebelo","year":"2023","journal-title":"Trends Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL-1-induced JAK\/STAT signaling is antagonized by TGF-\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"lyada","year":"2019","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","article-title":"Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.783617","article-title":"Heterogeneous pancreatic stellate cells are powerful contributors to the Malignant progression of pancreatic cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.01.001","article-title":"Targeting pancreatic stellate cells in cancer","volume":"5","author":"Schnittert","year":"2019","journal-title":"Trends Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322744","article-title":"Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism","volume":"71","author":"Sun","year":"2022","journal-title":"Gut"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","article-title":"EGFR-activated myofibroblasts promote metastasis of pancreatic cancer","volume":"42","author":"Mucciolo","year":"2024","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nat Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"B38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","article-title":"Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer","volume":"37","author":"Hegde","year":"2020","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41467-018-03600-6","article-title":"Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance","volume":"9","author":"Meyer","year":"2018","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0958","article-title":"Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Assessment of effects of durvalumab monotherapy and in combination with tremelimumab on objective response rate in patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007883","article-title":"Nivolumab alone or in combination with ipilimumab and\/or cobimetinib in advanced pancreatic cancer: Results from the CheckMate 032 study","volume":"12","author":"Callahan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European cohort","volume":"188","author":"Ta\u00efeb","year":"2023","journal-title":"Eur J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/pancan.2020.0021","article-title":"A phase 2 randomized placebo-controlled adjuvant trial of GI-4000, a recombinant yeast expressing mutated RAS proteins in patients with resected pancreas cancer","volume":"7","author":"Muscarella","year":"2021","journal-title":"J Pancreat Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): A single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02585","article-title":"Dendritic cell-based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"van 't Land","year":"2024","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"10609","DOI":"10.1038\/s41467-025-66092-1","article-title":"Dendritic cell vaccination with CD40 agonism in metastatic pancreatic cancer: The REACtiVe-2 phase 1 trial","volume":"16","author":"Kucukcelebi","year":"2025","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216456","article-title":"Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here","volume":"579","author":"Yoon","year":"2023","journal-title":"Cancer Lett"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200967","article-title":"Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin","volume":"33","author":"Sato-Dahlman","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200928","article-title":"KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis","volume":"33","author":"Otero-Mateo","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","article-title":"Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration","volume":"305","author":"Na","year":"2019","journal-title":"J Control Release"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.7150\/thno.40902","article-title":"Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses","volume":"10","author":"Brugada-Vil\u00e0","year":"2020","journal-title":"Theranostics"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e001624","DOI":"10.1136\/jitc-2020-001624","article-title":"A systemically deliverable vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer","volume":"9","author":"Marelli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15903","article-title":"Interferon-expressing oncolytic adenovirus\u2009+\u2009chemoradiation inhibited pancreatic cancer growth in a hamster model","volume":"114","author":"Shinoda","year":"2023","journal-title":"Cancer Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.027","article-title":"Reshaping the immune microenvironment by oncolytic herpes simplex virus in murine pancreatic ductal adenocarcinoma","volume":"29","author":"Zhang","year":"2021","journal-title":"Mol Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e003809","DOI":"10.1136\/jitc-2021-003809","article-title":"CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e001191","DOI":"10.1136\/jitc-2020-001191","article-title":"Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy","volume":"8","author":"Groeneveldt","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e004464","DOI":"10.1136\/jitc-2021-004464","article-title":"Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy","volume":"10","author":"Groeneveldt","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13603","article-title":"STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy","volume":"18","author":"Sibal","year":"2024","journal-title":"Mol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1096162","article-title":"Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model","volume":"13","author":"Veinalde","year":"2022","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013175","article-title":"Oncolytic virus-induced IL-1\u03b2+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01643-19","article-title":"Experimental evolution generates novel oncolytic vesicular stomatitis viruses with improved replication in virus-resistant pancreatic cancer cells","volume":"94","author":"Seegers","year":"2020","journal-title":"J Virol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.omto.2021.11.019","article-title":"Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus","volume":"24","author":"Goad","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01005-23","article-title":"Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells","volume":"97","author":"Goad","year":"2023","journal-title":"J Virol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02284-24","article-title":"METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of an intrinsic antiviral state","volume":"99","author":"Catacalos-Goad","year":"2025","journal-title":"J Virol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105219","article-title":"Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures","volume":"105","author":"Schafer","year":"2024","journal-title":"EBioMedicine"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201064","article-title":"Identifying gene expression signatures of oncolytic virus response in patient-derived pancreatic ductal adenocarcinoma organoids","volume":"33","author":"Huberts","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110969","article-title":"Inactivation of the DNA-sensing pathway facilitates oncolytic herpes simplex virus inhibition of pancreatic ductal adenocarcinoma growth","volume":"124","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.66","article-title":"Randomized phase 2 trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2833","article-title":"2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with\/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)","volume":"36","author":"Garcia-Carbonero","year":"2025","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): Results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"oyae200","DOI":"10.1093\/oncolo\/oyae200","article-title":"Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer","volume":"30","author":"Runcie","year":"2025","journal-title":"Oncologist"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.gie.2020.02.012","article-title":"Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: A phase 1 trial","volume":"92","author":"Lee","year":"2020","journal-title":"Gastrointest Endosc"},{"key":"B89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A Phase Ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060160","article-title":"A phase II study of pelareorep (reolysin) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma","volume":"10","author":"Mahalingam","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-023-12521-4","article-title":"Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application","volume":"107","author":"Frehtman","year":"2023","journal-title":"Appl Microbiol Biotechnol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-021-11642-y","article-title":"Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus","volume":"105","author":"Wohlfarth","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.1038\/s41467-024-49450-3","article-title":"In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer","volume":"15","author":"Martinez","year":"2024","journal-title":"Nat Commun"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00060-y","article-title":"Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.7150\/thno.46642","article-title":"Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression","volume":"10","author":"Jiang","year":"2020","journal-title":"Theranostics"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000875","article-title":"Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer","volume":"4","author":"McAndrews","year":"2021","journal-title":"Life Sci Alliance"},{"key":"B99","volume-title":"Human gene therapy products incorporating human genome editing: Guidance for industry","year":"2024"},{"key":"B100","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","article-title":"CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer","volume":"16","author":"Qi","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02314","article-title":"Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: A pooled analysis of two early-phase trials","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e006130","DOI":"10.1136\/jitc-2022-006130","article-title":"Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216366","article-title":"Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC","volume":"573","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216741","article-title":"Antigen\/HLA-agnostic strategies for characterizing tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application","volume":"588","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B109","volume-title":"Considerations for the development of chimeric antigen receptor (CAR) T cell products: Guidance for industry","year":"2024"},{"key":"B110","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.medj.2024.02.012","article-title":"Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer","volume":"5","author":"Li","year":"2024","journal-title":"Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202206765","article-title":"Dual-cascade responsive nanoparticles enhance pancreatic cancer therapy by eliminating tumor-resident intracellular bacteria","volume":"34","author":"Kang","year":"2022","journal-title":"Adv Mater"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216810","article-title":"Biodistribution and therapeutic efficacy of a gold nanoparticle-based targeted drug delivery system against pancreatic cancer","volume":"589","author":"Elechalawar","year":"2024","journal-title":"Cancer Lett"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2022.03.050","article-title":"Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming","volume":"145","author":"Zhao","year":"2022","journal-title":"Acta Biomater"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114567","article-title":"Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment","volume":"161","author":"Lin","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310456","article-title":"Platinum prodrug nanoparticles with COX-2 inhibition amplify pyroptosis for enhanced chemotherapy and immune activation of pancreatic cancer","volume":"36","author":"Yu","year":"2024","journal-title":"Adv Mater"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116660","article-title":"Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation","volume":"175","author":"Lo","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B117","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12951-024-02369-9","article-title":"Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","article-title":"Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors","volume":"357","author":"Anthiya","year":"2023","journal-title":"J Control Release"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3189","article-title":"A phase II trial of an extended-release siRNA implant targeting KRASG12D\/V in locally advanced pancreatic cancer","volume":"32","author":"Alagesan","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","article-title":"Engineered exosomes with KRASG12D-specific siRNA in pancreatic cancer: a phase I study with immunological correlates","volume":"16","author":"Kalluri","year":"2025","journal-title":"Nat Commun"},{"key":"B121","volume-title":"Drug products, including biological products, that contain nanomaterials: Guidance for industry","year":"2022"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1038\/s41467-023-39026-y","article-title":"Pacpaint: A histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma","volume":"14","author":"Saillard","year":"2023","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12967-024-05590-0","article-title":"Machine learning-based identification of biomarkers and drugs in immunologically cold and hot pancreatic adenocarcinomas","volume":"22","author":"Ge","year":"2024","journal-title":"J Transl Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0873","article-title":"Machine learning links T-cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer","volume":"12","author":"Blise","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1038\/s41467-025-56818-6","article-title":"AI-driven discovery of synergistic drug combinations against pancreatic cancer","volume":"16","author":"Pourmousa","year":"2025","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.010","article-title":"Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma","volume":"35","author":"Fraunhoffer","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:59:05Z","timestamp":1789387145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":126,"alternative-id":["10.3389\/fimmu.2026.1900936"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1900936","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1900936"}}